High-grade gliomas driven by alterations in MAPK pathway showed enrichment of immune-response pathways, including elevated M2-macrophage and CD8+ T cell signatures, compared to non-MAPK altered gliomas (90). This evidence concerns the gene CD8A and central nervous system cancer.